Kayentis provides electronic Clinical Outcome Assessment (eCOA) and decentralized/hybrid clinical trial (DCT) solutions to pharma, biotech and CROs. Led by CEO Guillaume Juge and active since 2003, the company supports phases II/III across a broad range of therapeutic areas and has expanded its services beyond eCOA to meet decentralized trial needs. Kayentis has conducted digital data collection for over 280 clinical trials in 85 countries, covering 18,000 sites and 98,000 patients in 120 languages, and employs 185 staff. It maintains offices in Boston, Grenoble and Tokyo and reports that U.S.-based sponsor teams lead about one-third of its projects. The company raised an additional €5M—€2.2M as increased capital from LBO France, Extens and Bpifrance and €2.8M in bank loans—to support growth. Kayentis intends to use the funds to scale up its North American operations to support clinical trials. Kayentis provides digital data capture technologies and eCOA solutions for sponsors, sites and patients in clinical trials, with a focus on phase II/III research. The company has been active in clinical development since 2003 and has specialized in eCOA over the past ten years while expanding into hybrid and decentralized trials. Its core product is the Clin’form3 eCOA platform, which Kayentis is enriching with new functions and apps to integrate with other clinical databases and adapt to clinical workflows. Kayentis has conducted digital data collection for over 220 clinical trials in 79 countries, covering 13,000 sites, 80,000 patients and 120 languages. Headquartered in Grenoble, France, the company also has operations in Boston and Tokyo and is led by CEO Guillaume Juge. The company plans to improve patient and site experience through televisits, eConsent and wearable integrations and to intensify US development. Kayentis develops electronic clinical outcome assessment (eCOA) solutions delivered via web portals and mobile tools, including patient-reported, clinician-reported, and observer-reported outcomes, automatic remote testing, and patient diaries. The company emphasizes patient engagement to improve data quality, compliance, and trial efficiency. It is a seven-year-old French firm whose platform has been used in more than 120 trials across 75 countries, impacting roughly 50,000 patients. Kayentis raised $3.9 million (3.6 million euros) in the reported funding round to support its growth. Management says the financing validates its development model and growth prospects and will fund continued platform improvements and value-added services. The company plans to use the funds to accelerate international expansion and to grow its sales, marketing, and R&D teams.

Total raised

$18M

Funding rounds

4

Latest round

Equity

Latest activity

Mar 2023